LINC01123: a pan-cancer “molecular commander” deciphering the CeRNA network atlas for precision diagnosis and therapy

LINC01123, a long non-coding RNA (lncRNA) encoded on chromosome 2q13, is a crucial regulator in various human cancers. It spans 8,302 nucleotides and is implicated in malignancies like lung, ovarian, colorectal, head and neck, oral, cervical, breast, cholangiocarcinoma, and hepatocellular cancers. LINC01123 acts as a competitive endogenous RNA (ceRNA), sequestering microRNAs such as miR-199a-5p, miR-151a, miR-34c-5p, miR-625-5p, miR-542-3p, and miR-34a-5p to modulate downstream target genes including c-MYC, VEGFA, and AXL. These interactions affect signaling pathways like NOTCH, MAPK, and PI3K-AKT, promoting cancer hallmarks such as cell proliferation, metastasis, angiogenesis, metabolic reprogramming, immune evasion, and radio/chemotherapy resistance. Recent studies suggest LINC01123 also has potential therapeutic roles in vascular and neurological disorders like acute cerebral infarction and venous thromboembolism. Thus, LINC01123 is a promising multi-disease intervention target warranting further exploration of its molecular pathways and clinical applications.